You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
In Situ Production of Biocidal Reactive Oxygen via Directed Energy
SBC: Zeteo Tech, Inc. Topic: NonDoDThis effort will expand the universe of direct energy enhancers across a wider spectrum of RF parameters to produce optimal decontamination at even lower cost. During the course of the Phase II investigation proposed here, initial work will be carried out on the determination of the fundamental mechanism of decontamination of biological materials with an eye toward expanding applicability to chemi ...
SBIR Phase II 2019 Department of DefenseOffice for Chemical and Biological Defense -
AOTF Based Spectro-Polarimetric Imaging System for Stand-off Chemical Detection
SBC: BRIMROSE TECHNOLOGY CORP Topic: CBD13104Our goal in this SBIR project is to develop a lightweight, low-power, inexpensive hyperspectral spectro-polarimetric imaging sensor for wide area standoff detection of chemical agents. The imaging system will employ an acousto-optic tunable filter (AOTF) that operates in the LWIR wavelength range. The sensor will have polarimetric imaging capabilities which, adds a valuable signature feature to im ...
SBIR Phase II 2019 Department of DefenseOffice for Chemical and Biological Defense -
Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment
SBC: ZYMERON CORPORATION Topic: CBD181004Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...
SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense